Astec LifeSciences（ASTEC）株式概要アステック・ライフサイエンシズ社は、その子会社とともに、インドにおいて農薬原体および医薬中間体の製造・販売を行っている。 詳細ASTEC ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長5/6過去の実績0/6財務の健全性1/6配当金0/6報酬当社が推定した公正価値より3%で取引されている 収益は年間104.75%増加すると予測されています リスク分析負債は営業キャッシュフローで十分にカバーされていない すべてのリスクチェックを見るASTEC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW481,888 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA481,888 investors already sharing narrativesYour Fair Value₹Current Price₹620.3583.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1b13b2016201920222025202620282031Revenue ₹13.1bEarnings ₹1.2bAdvancedSet Fair ValueView all narrativesAstec LifeSciences Limited 競合他社Madras FertilizersSymbol: NSEI:MADRASFERTMarket cap: ₹10.8bExcel IndustriesSymbol: BSE:500650Market cap: ₹13.0bSouthern Petrochemical IndustriesSymbol: BSE:590030Market cap: ₹14.0bMeghmani OrganicsSymbol: NSEI:MOLMarket cap: ₹13.3b価格と性能株価の高値、安値、推移の概要Astec LifeSciences過去の株価現在の株価₹620.6552週高値₹941.7552週安値₹513.40ベータ0.201ヶ月の変化-9.95%3ヶ月変化-7.57%1年変化-21.07%3年間の変化-52.96%5年間の変化-51.20%IPOからの変化638.87%最新ニュースReported Earnings • Aug 03First quarter 2027 earnings: EPS misses analyst expectationsFirst quarter 2027 results: ₹8.40 loss per share (improved from ₹16.86 loss in 1Q 2026). Revenue: ₹842.9m (down 7.5% from 1Q 2026). Net loss: ₹187.2m (loss narrowed 43% from 1Q 2026). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.2%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.お知らせ • Jul 21Astec LifeSciences Limited to Report Q1, 2027 Results on Jul 31, 2026Astec LifeSciences Limited announced that they will report Q1, 2027 results on Jul 31, 2026Board Change • Jul 20High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Mathew Eipe was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Jul 12Price target decreased by 18% to ₹623Down from ₹758, the current price target is an average from 2 analysts. New target price is 9.7% below last closing price of ₹689. Stock is down 23% over the past year. The company is forecast to post earnings per share of ₹9.70 next year compared to a net loss per share of ₹37.79 last year.Reported Earnings • Apr 29Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2026 results: ₹37.79 loss per share (improved from ₹68.71 loss in FY 2025). Revenue: ₹4.53b (up 19% from FY 2025). Net loss: ₹809.2m (loss narrowed 40% from FY 2025). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 61%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.お知らせ • Apr 28Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026, at 16:00 Indian Standard Time.最新情報をもっと見るRecent updatesReported Earnings • Aug 03First quarter 2027 earnings: EPS misses analyst expectationsFirst quarter 2027 results: ₹8.40 loss per share (improved from ₹16.86 loss in 1Q 2026). Revenue: ₹842.9m (down 7.5% from 1Q 2026). Net loss: ₹187.2m (loss narrowed 43% from 1Q 2026). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.2%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.お知らせ • Jul 21Astec LifeSciences Limited to Report Q1, 2027 Results on Jul 31, 2026Astec LifeSciences Limited announced that they will report Q1, 2027 results on Jul 31, 2026Board Change • Jul 20High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Mathew Eipe was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Price Target Changed • Jul 12Price target decreased by 18% to ₹623Down from ₹758, the current price target is an average from 2 analysts. New target price is 9.7% below last closing price of ₹689. Stock is down 23% over the past year. The company is forecast to post earnings per share of ₹9.70 next year compared to a net loss per share of ₹37.79 last year.Reported Earnings • Apr 29Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2026 results: ₹37.79 loss per share (improved from ₹68.71 loss in FY 2025). Revenue: ₹4.53b (up 19% from FY 2025). Net loss: ₹809.2m (loss narrowed 40% from FY 2025). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 61%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.お知らせ • Apr 28Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026, at 16:00 Indian Standard Time.お知らせ • Apr 18Astec LifeSciences Limited to Report Q4, 2026 Results on Apr 27, 2026Astec LifeSciences Limited announced that they will report Q4, 2026 results on Apr 27, 2026お知らせ • Apr 14+ 1 more updateAstec Lifesciences Limited Announces Board AppointmentsAstec LifeSciences Limited announced that Vishal Sharma, the chief executive of Godrej Chemicals, took over as the chairperson of Astec LifeSciences with immediate effect on April 13, 2026. Arijit Mukherjee, the company's chief operating officer, will be appointed as an executive director.New Risk • Mar 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).お知らせ • Mar 10Clean Max Enviro Energy Solutions Limited (NSEI:CLEANMAX) entered into an agreement to acquire an additional 26% stake in Clean Max Andes Private Limited from Astec LifeSciences Limited (NSEI:ASTEC) for INR 0.03 million.Clean Max Enviro Energy Solutions Limited (NSEI:CLEANMAX) entered into an agreement to acquire an additional 26% stake in Clean Max Andes Private Limited from Astec LifeSciences Limited (NSEI:ASTEC) for INR 0.03 million on March 9, 2026. A cash consideration of INR 0.03 million will be paid by Clean Max Enviro Energy Solutions Limited. As part of consideration, INR 0.03 million is paid towards common equity of Clean Max Andes Private Limited. The expected completion of the transaction is March 10, 2026.Price Target Changed • Feb 15Price target decreased by 10% to ₹758Down from ₹845, the current price target is an average from 2 analysts. New target price is 19% above last closing price of ₹637. Stock is down 25% over the past year. The company is forecast to post a net loss per share of ₹22.50 next year compared to a net loss per share of ₹68.71 last year.Reported Earnings • Feb 01Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: ₹7.04 loss per share (improved from ₹20.60 loss in 3Q 2025). Revenue: ₹1.26b (up 34% from 3Q 2025). Net loss: ₹157.0m (loss narrowed 61% from 3Q 2025). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 44%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.お知らせ • Jan 20Astec LifeSciences Limited to Report Q3, 2026 Results on Jan 30, 2026Astec LifeSciences Limited announced that they will report Q3, 2026 results on Jan 30, 2026分析記事 • Nov 25Astec LifeSciences Limited (NSE:ASTEC) Looks Just Right With A 33% Price JumpAstec LifeSciences Limited ( NSE:ASTEC ) shareholders would be excited to see that the share price has had a great...分析記事 • Nov 21Astec LifeSciences (NSE:ASTEC) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).Reported Earnings • Oct 31Second quarter 2026 earnings: EPS and revenues miss analyst expectationsSecond quarter 2026 results: ₹11.35 loss per share (improved from ₹19.66 loss in 2Q 2025). Revenue: ₹748.4m (down 24% from 2Q 2025). Net loss: ₹244.3m (loss narrowed 37% from 2Q 2025). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.お知らせ • Oct 14Astec LifeSciences Limited to Report Q2, 2026 Results on Oct 29, 2025Astec LifeSciences Limited announced that they will report Q2, 2026 results on Oct 29, 2025New Risk • Aug 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Ganapati Yadav was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 30Astec LifeSciences Limited has completed a Follow-on Equity Offering in the amount of INR 2.376256 billion.Astec LifeSciences Limited has completed a Follow-on Equity Offering in the amount of INR 2.376256 billion. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,669,951 Price\Range: INR 890 Transaction Features: Regulation S; Rights Offeringお知らせ • Jul 11Astec LifeSciences Limited to Report Q1, 2026 Results on Jul 28, 2025Astec LifeSciences Limited announced that they will report Q1, 2026 results on Jul 28, 2025Reported Earnings • Jul 09Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₹68.71 loss per share (further deteriorated from ₹23.94 loss in FY 2024). Revenue: ₹3.81b (down 17% from FY 2024). Net loss: ₹1.35b (loss widened 187% from FY 2024). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance.お知らせ • Jun 25Astec LifeSciences Limited has filed a Follow-on Equity Offering in the amount of INR 2.5 billion.Astec LifeSciences Limited has filed a Follow-on Equity Offering in the amount of INR 2.5 billion. Security Name: Equity Shares Security Type: Common Stock Transaction Features: Regulation S; Rights Offeringお知らせ • Apr 24Astec LifeSciences Limited, Annual General Meeting, Jul 28, 2025Astec LifeSciences Limited, Annual General Meeting, Jul 28, 2025, at 16:00 Indian Standard Time.Reported Earnings • Apr 24Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₹68.71 loss per share (further deteriorated from ₹23.94 loss in FY 2024). Revenue: ₹3.87b (down 16% from FY 2024). Net loss: ₹1.35b (loss widened 187% from FY 2024). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.お知らせ • Apr 16Astec LifeSciences Limited to Report Q4, 2025 Results on Apr 23, 2025Astec LifeSciences Limited announced that they will report Q4, 2025 results at 4:00 PM, Indian Standard Time on Apr 23, 2025分析記事 • Feb 19The Price Is Right For Astec LifeSciences Limited (NSE:ASTEC) Even After Diving 30%Astec LifeSciences Limited ( NSE:ASTEC ) shareholders that were waiting for something to happen have been dealt a blow...Price Target Changed • Feb 18Price target decreased by 8.6% to ₹1,010Down from ₹1,105, the current price target is an average from 2 analysts. New target price is 42% above last closing price of ₹710. Stock is down 24% over the past year. The company is forecast to post a net loss per share of ₹56.90 next year compared to a net loss per share of ₹23.93 last year.New Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.4% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change).Reported Earnings • Jan 28Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: ₹20.59 loss per share (further deteriorated from ₹12.41 loss in 3Q 2024). Revenue: ₹957.7m (up 89% from 3Q 2024). Net loss: ₹403.8m (loss widened 66% from 3Q 2024). Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 102%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.お知らせ • Jan 20Astec LifeSciences Limited to Report Q3, 2025 Results on Jan 27, 2025Astec LifeSciences Limited announced that they will report Q3, 2025 results on Jan 27, 2025分析記事 • Jan 04Why We're Not Concerned About Astec LifeSciences Limited's (NSE:ASTEC) Share PriceWhen you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...お知らせ • Dec 15Astec Lifesciences Limited Announces Appointment of Arijit Mukherjee as the ManagerAstec LifeSciences Limited passed resolution on December 14, 2024, Appointment of Mr. Arijit Mukherjee, Chief Operating Officer, as the "Manager" of the Company (within the meaning of Section 2(53) of the Companies Act, 2013) with effect from 26th October, 2024 for a term of 3 (Three) years, i.e., upto 25th October, 2027, has been approved by the Shareholders by way of a Special Resolution.Reported Earnings • Oct 26Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: ₹19.66 loss per share (further deteriorated from ₹6.85 loss in 2Q 2024). Revenue: ₹1.01b (down 9.2% from 2Q 2024). Net loss: ₹385.6m (loss widened 187% from 2Q 2024). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.お知らせ • Oct 04Astec Lifesciences Limited Announces Resignation of Brahma Nand Vyas as an Independent DirectorAstec LifeSciences Limited announced that Dr. Brahma Nand Vyas has tendered his resignation as an Independent Director of the Company with effect from closure of business hours on 4th October, 2024, due to his advancing age. Reason for Change: Dr. Brahma Nand Vyas has tendered his resignation as an Independent Director of the Company, with effect from closure of business hours on 4th October, 2024, due to his advancing age.お知らせ • Sep 23Astec Lifesciences Limited Announces Resignation of Anurag Roy as Chief Executive Officer, Effective October 25, 2024Astec LifeSciences Limited announced that Mr. Anurag Roy has tendered his resignation as Chief Executive Officer with effect from closure of business hours on 25th October, 2024. Reason for Change: Mr. Anurag Roy has tendered his resignation as the Whole Time Director & Chief Executive Officer of the Company, with effect from closure of business hours on 25th October, 2024, for pursuing opportunities outside the Company. Date of Cessation: Closure of business hours on 25th October, 2024.Price Target Changed • Sep 23Price target decreased by 14% to ₹1,090Down from ₹1,273, the current price target is an average from 2 analysts. New target price is 9.3% below last closing price of ₹1,202. Stock is down 8.4% over the past year. The company is forecast to post earnings per share of ₹10.30 next year compared to a net loss per share of ₹23.93 last year.お知らせ • Sep 23Astec Lifesciences Limited Announces Resignation of Anurag Roy as the Whole Time Director, Effective October 25, 2024Astec LifeSciences Limited announced that Mr. Anurag Roy has tendered his resignation as the Whole Time Director of the Company with effect from closure of business hours on 25th October, 2024. Reason for Change: Mr. Anurag Roy has tendered his resignation as the Whole Time Director & Chief Executive Officer of the Company, with effect from closure of business hours on 25th October, 2024, for pursuing opportunities outside the Company. Date of Cessation: Closure of business hours on 25th October, 2024.New Risk • Aug 07New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.1% operating cash flow to total debt). Earnings have declined by 31% per year over the past 5 years.Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Additional Non-Executive Non- Independent Director Burjis Godrej was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Jul 23Shareholders May Be Wary Of Increasing Astec LifeSciences Limited's (NSE:ASTEC) CEO Compensation PackageKey Insights Astec LifeSciences' Annual General Meeting to take place on 29th of July Total pay for CEO Anurag Roy...お知らせ • Jul 18Astec LifeSciences Limited to Report Q1, 2025 Results on Jul 29, 2024Astec LifeSciences Limited announced that they will report Q1, 2025 results on Jul 29, 2024Reported Earnings • Jul 08Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: ₹23.94 loss per share (down from ₹13.04 profit in FY 2023). Revenue: ₹4.59b (down 27% from FY 2023). Net loss: ₹469.3m (down 284% from profit in FY 2023). Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.分析記事 • Jul 03Market Participants Recognise Astec LifeSciences Limited's (NSE:ASTEC) Revenues Pushing Shares 28% HigherAstec LifeSciences Limited ( NSE:ASTEC ) shareholders have had their patience rewarded with a 28% share price jump in...お知らせ • May 03Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024, at 16:00 Indian Standard Time.Reported Earnings • May 03Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: ₹0.50 loss per share (down from ₹13.04 profit in FY 2023). Revenue: ₹1.56b (down 75% from FY 2023). Net loss: ₹9.74m (down 104% from profit in FY 2023). Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.お知らせ • May 03+ 1 more updateAstec Lifesciences Limited Announces Resignation of Mr. K. Suryanarayan as Chief Financial Officer, Effective May 3, 2024Astec LifeSciences Limited noted the resignation of Mr. K. Suryanarayan from the position of "Chief Financial Officer" of the Company with effect from the close of business hours on 3rd May, 2024.お知らせ • Apr 26Astec LifeSciences Limited to Report Q4, 2024 Results on May 02, 2024Astec LifeSciences Limited announced that they will report Q4, 2024 results on May 02, 2024Price Target Changed • Apr 14Price target decreased by 14% to ₹1,108Down from ₹1,285, the current price target is an average from 2 analysts. New target price is 14% below last closing price of ₹1,289. Stock is down 5.2% over the past year. The company is forecast to post a net loss per share of ₹21.70 compared to earnings per share of ₹13.04 last year.分析記事 • Mar 15Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks ReasonableThose holding Astec LifeSciences Limited ( NSE:ASTEC ) shares would be relieved that the share price has rebounded 30...Price Target Changed • Jan 28Price target decreased by 9.3% to ₹1,205Down from ₹1,328, the current price target is an average from 2 analysts. New target price is 20% above last closing price of ₹1,001. Stock is down 35% over the past year. The company posted earnings per share of ₹13.04 last year.Reported Earnings • Jan 27Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023)Third quarter 2024 results: ₹12.41 loss per share (down from ₹0.43 profit in 3Q 2023). Revenue: ₹517.0m (down 56% from 3Q 2023). Net loss: ₹243.3m (down ₹251.7m from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Jan 13Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024Astec LifeSciences Limited announced that they will report Q3, 2024 results at 4:00 PM, Indian Standard Time on Jan 25, 2024Reported Earnings • Oct 29Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023)Second quarter 2024 results: ₹6.85 loss per share (down from ₹9.34 profit in 2Q 2023). Revenue: ₹1.12b (down 44% from 2Q 2023). Net loss: ₹134.3m (down 173% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.お知らせ • Oct 11Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023Astec LifeSciences Limited announced that they will report Q2, 2024 results on Oct 27, 2023お知らせ • Jul 29Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023Astec LifeSciences Limited announced at the AGM held on July 27, 2023, approved to declare final dividend on equity share @15%(that is INR 1.5) per equity share of face value of INR 10 for the financial year ended March 31, 2023.お知らせ • Jul 23Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023Astec LifeSciences Limited announced that they will report Q1, 2024 results on Jul 27, 2023Upcoming Dividend • Jul 14Upcoming dividend of ₹1.50 per share at 0.1% yieldEligible shareholders must have bought the stock before 21 July 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 12% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%).Reported Earnings • Jul 08Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)Full year 2023 results: EPS: ₹13.04 (down from ₹45.87 in FY 2022). Revenue: ₹6.28b (down 7.2% from FY 2022). Net income: ₹255.6m (down 72% from FY 2022). Profit margin: 4.1% (down from 13% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Jun 10Non-Executive Non-Independent Director recently sold ₹4.8m worth of stockOn the 6th of June, Balram Yadav sold around 3k shares on-market at roughly ₹1,407 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.分析記事 • May 17Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...お知らせ • May 04Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023Astec LifeSciences Limited at its board meeting held on May 2, 2023, recommended Final Dividend of 15% on the Equity Share Capital of the Company that is INR 1.50 per Equity Share of Face Value of INR 10 each for the Financial Year ended March 31, 2023, subject To Approve the Shareholders at the upcoming 29th Annual General Meeting of the Company. The Book Closure Dates for the purposes of the 29th Annual General Meeting and payment of Final Dividend are from July 22, 2023 to July 26, 2023, during which the Register of Members and Share Transfer Books will remain closed. The dividend will be paid by August 1, 2023.Reported Earnings • May 03Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)Full year 2023 results: EPS: ₹13.04 (down from ₹45.87 in FY 2022). Revenue: ₹6.41b (down 5.3% from FY 2022). Net income: ₹255.6m (down 72% from FY 2022). Profit margin: 4.0% (down from 13% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹1,346, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 204% over the past three years.Reported Earnings • Jan 31Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.43 (down from ₹12.63 in 3Q 2022). Revenue: ₹1.21b (down 30% from 3Q 2022). Net income: ₹8.40m (down 97% from 3Q 2022). Profit margin: 0.7% (down from 14% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jan 12Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023Astec LifeSciences Limited announced that they will report Q3, 2023 results on Jan 30, 2023Price Target Changed • Jan 05Price target decreased to ₹1,923Down from ₹2,083, the current price target is an average from 3 analysts. New target price is 11% above last closing price of ₹1,739. Stock is up 19% over the past year. The company is forecast to post earnings per share of ₹46.90 for next year compared to ₹45.87 last year.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive Non- Independent Director Burjis Godrej was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 03Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022)Second quarter 2023 results: EPS: ₹9.34 (up from ₹4.63 in 2Q 2022). Revenue: ₹2.00b (up 95% from 2Q 2022). Net income: ₹183.1m (up 102% from 2Q 2022). Profit margin: 9.2% (up from 8.8% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹2,176, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 525% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹3,619 per share.分析記事 • Oct 14Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In ValueIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Price Target Changed • Aug 30Price target increased to ₹2,132Up from ₹1,875, the current price target is an average from 2 analysts. New target price is 10% above last closing price of ₹1,930. Stock is up 48% over the past year. The company is forecast to post earnings per share of ₹50.00 for next year compared to ₹45.87 last year.Board Change • Aug 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive Non- Independent Director Burjis Godrej was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.分析記事 • Jul 27We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With EaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Upcoming Dividend • Jul 12Upcoming dividend of ₹1.50 per shareEligible shareholders must have bought the stock before 19 July 2022. Payment date: 29 July 2022. Payout ratio is a comfortable 3.3% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (0.8%).Reported Earnings • Jul 06Full year 2022 earnings: Revenues exceed analyst expectationsFull year 2022 results: Net income: ₹898.6m (up 38% from FY 2021). Revenue exceeded analyst estimates by 3.8%.分析記事 • Jun 28Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt ResponsiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jun 03A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Astec LifeSciences...Price Target Changed • May 19Price target increased to ₹1,869Up from ₹1,722, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹1,794. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₹54.93 for next year compared to ₹45.87 last year.Major Estimate Revision • May 09Consensus revenue estimates increase by 11%The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from ₹7.68b to ₹8.52b. EPS estimate increased from ₹48.30 to ₹54.93 per share. Net income forecast to grow 24% next year vs 25% growth forecast for Chemicals industry in India. Consensus price target up from ₹1,722 to ₹1,812. Share price fell 3.9% to ₹1,874 over the past week.分析記事 • May 08Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)Shareholders in Astec LifeSciences Limited ( NSE:ASTEC ) may be thrilled to learn that the analysts have just delivered...分析記事 • May 06Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsAstec LifeSciences Limited ( NSE:ASTEC ) investors will be delighted, with the company turning in some strong numbers...Reported Earnings • May 04Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₹45.87 (up from ₹33.23 in FY 2021). Revenue: ₹6.87b (up 23% from FY 2021). Net income: ₹898.6m (up 38% from FY 2021). Profit margin: 13% (up from 12% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 12%, compared to a 21% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.Recent Insider Transactions • Apr 02MD & Director recently bought ₹37m worth of stockOn the 25th of March, Ashok Hiremath bought around 22k shares on-market at roughly ₹1,701 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹213m more in shares than they bought in the last 12 months.Recent Insider Transactions • Mar 11Non-Executive Non-Independent Director recently bought ₹1.5m worth of stockOn the 7th of March, Balram Yadav bought around 1k shares on-market at roughly ₹1,481 per share. In the last 3 months, they made an even bigger purchase worth ₹3.5m. Despite this recent purchase, insiders have collectively sold ₹251m more in shares than they bought in the last 12 months.Recent Insider Transactions • Mar 06Non-Executive Non-Independent Director recently bought ₹3.5m worth of stockOn the 28th of February, Balram Yadav bought around 2k shares on-market at roughly ₹1,467 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹252m more in shares than they bought in the last 12 months.Reported Earnings • Jan 26Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: ₹12.63 (up from ₹3.61 in 3Q 2021). Revenue: ₹1.75b (up 51% from 3Q 2021). Net income: ₹247.5m (up 251% from 3Q 2021). Profit margin: 14% (up from 6.1% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 24%, compared to a 19% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Jan 25Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Recent Insider Transactions • Dec 18Insider recently sold ₹1.5m worth of stockOn the 13th of December, Ramesh Pingale sold around 1k shares on-market at roughly ₹1,508 per share. In the last 3 months, they made an even bigger sale worth ₹2.4m. Insiders have been net sellers, collectively disposing of ₹254m more than they bought in the last 12 months.Recent Insider Transactions • Dec 18Insider recently sold ₹1.5m worth of stockOn the 13th of December, Ramesh Pingale sold around 1k shares on-market at roughly ₹1,508 per share. In the last 3 months, they made an even bigger sale worth ₹2.4m. Insiders have been net sellers, collectively disposing of ₹254m more than they bought in the last 12 months.分析記事 • Dec 13Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹1,553, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 202% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹952 per share.Recent Insider Transactions • Nov 20Insider recently sold ₹2.4m worth of stockOn the 15th of November, Ramesh Pingale sold around 2k shares on-market at roughly ₹1,401 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹253m more than they bought in the last 12 months.Price Target Changed • Nov 16Price target increased to ₹1,508Up from ₹1,392, the current price target is an average from 3 analysts. New target price is 10% above last closing price of ₹1,367. Stock is up 39% over the past year. The company is forecast to post earnings per share of ₹39.25 for next year compared to ₹33.23 last year.Price Target Changed • Aug 01Price target increased to ₹1,386Up from ₹1,284, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹1,388. Stock is up 48% over the past year.分析記事 • Jul 21We Take A Look At Why Astec LifeSciences Limited's (NSE:ASTEC) CEO Has Earned Their Pay PacketWe have been pretty impressed with the performance at Astec LifeSciences Limited ( NSE:ASTEC ) recently and CEO Ashok...株主還元ASTECIN ChemicalsIN 市場7D-1.2%1.7%1.3%1Y-21.1%1.3%5.9%株主還元を見る業界別リターン: ASTEC過去 1 年間で1.3 % の収益を上げたIndian Chemicals業界を下回りました。リターン対市場: ASTECは、過去 1 年間で5.9 % のリターンを上げたIndian市場を下回りました。価格変動Is ASTEC's price volatile compared to industry and market?ASTEC volatilityASTEC Average Weekly Movement5.8%Chemicals Industry Average Movement6.0%Market Average Movement5.9%10% most volatile stocks in IN Market9.0%10% least volatile stocks in IN Market3.7%安定した株価: ASTEC 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: ASTECの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1994471n/awww.godrejastec.comAstec LifeSciences Limited は、子会社とともにインドで農薬活性成分および医薬中間体の製造・販売を行っている。畑作用のトリアゾール系殺菌剤、かさぶた病、うどんこ病、ショットホール病、花枯病、さび病防除のための葉面処理剤、綿花やトウモロコシ、大麦、米、小麦などの穀物における種子および土壌伝染性病害防除のための種子処理剤、ポストハーベストドレンチ、食品添加物、木材保存剤などを提供している。また、除草剤、殺虫剤、特殊化学製品も提供している。製品の輸出も行っている。同社は1994年に設立され、インドのムンバイを拠点としている。Astec LifeSciences Limited は Godrej Agrovet Limited の子会社である。もっと見るAstec LifeSciences Limited 基礎のまとめAstec LifeSciences の収益と売上を時価総額と比較するとどうか。ASTEC 基礎統計学時価総額₹13.83b収益（TTM）-₹665.97m売上高(TTM)₹4.41b3.1xP/Sレシオ-20.8xPER（株価収益率ASTEC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ASTEC 損益計算書（TTM）収益₹4.41b売上原価₹2.87b売上総利益₹1.54bその他の費用₹2.20b収益-₹665.97m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）-29.89グロス・マージン34.86%純利益率-15.11%有利子負債／自己資本比率114.8%ASTEC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/10 18:57終値2026/08/10 00:00収益2026/06/30年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Astec LifeSciences Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関null nullAsian Markets Securities Private LimitedAnkur PeriwalAxis Capital LimitedSatish KumarCGS International3 その他のアナリストを表示
Reported Earnings • Aug 03First quarter 2027 earnings: EPS misses analyst expectationsFirst quarter 2027 results: ₹8.40 loss per share (improved from ₹16.86 loss in 1Q 2026). Revenue: ₹842.9m (down 7.5% from 1Q 2026). Net loss: ₹187.2m (loss narrowed 43% from 1Q 2026). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.2%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 21Astec LifeSciences Limited to Report Q1, 2027 Results on Jul 31, 2026Astec LifeSciences Limited announced that they will report Q1, 2027 results on Jul 31, 2026
Board Change • Jul 20High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Mathew Eipe was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Jul 12Price target decreased by 18% to ₹623Down from ₹758, the current price target is an average from 2 analysts. New target price is 9.7% below last closing price of ₹689. Stock is down 23% over the past year. The company is forecast to post earnings per share of ₹9.70 next year compared to a net loss per share of ₹37.79 last year.
Reported Earnings • Apr 29Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2026 results: ₹37.79 loss per share (improved from ₹68.71 loss in FY 2025). Revenue: ₹4.53b (up 19% from FY 2025). Net loss: ₹809.2m (loss narrowed 40% from FY 2025). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 61%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 28Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026, at 16:00 Indian Standard Time.
Reported Earnings • Aug 03First quarter 2027 earnings: EPS misses analyst expectationsFirst quarter 2027 results: ₹8.40 loss per share (improved from ₹16.86 loss in 1Q 2026). Revenue: ₹842.9m (down 7.5% from 1Q 2026). Net loss: ₹187.2m (loss narrowed 43% from 1Q 2026). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.2%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 21Astec LifeSciences Limited to Report Q1, 2027 Results on Jul 31, 2026Astec LifeSciences Limited announced that they will report Q1, 2027 results on Jul 31, 2026
Board Change • Jul 20High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Independent Director Mathew Eipe was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Price Target Changed • Jul 12Price target decreased by 18% to ₹623Down from ₹758, the current price target is an average from 2 analysts. New target price is 9.7% below last closing price of ₹689. Stock is down 23% over the past year. The company is forecast to post earnings per share of ₹9.70 next year compared to a net loss per share of ₹37.79 last year.
Reported Earnings • Apr 29Full year 2026 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2026 results: ₹37.79 loss per share (improved from ₹68.71 loss in FY 2025). Revenue: ₹4.53b (up 19% from FY 2025). Net loss: ₹809.2m (loss narrowed 40% from FY 2025). Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) missed analyst estimates by 61%. Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 28Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026Astec LifeSciences Limited, Annual General Meeting, Jul 31, 2026, at 16:00 Indian Standard Time.
お知らせ • Apr 18Astec LifeSciences Limited to Report Q4, 2026 Results on Apr 27, 2026Astec LifeSciences Limited announced that they will report Q4, 2026 results on Apr 27, 2026
お知らせ • Apr 14+ 1 more updateAstec Lifesciences Limited Announces Board AppointmentsAstec LifeSciences Limited announced that Vishal Sharma, the chief executive of Godrej Chemicals, took over as the chairperson of Astec LifeSciences with immediate effect on April 13, 2026. Arijit Mukherjee, the company's chief operating officer, will be appointed as an executive director.
New Risk • Mar 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
お知らせ • Mar 10Clean Max Enviro Energy Solutions Limited (NSEI:CLEANMAX) entered into an agreement to acquire an additional 26% stake in Clean Max Andes Private Limited from Astec LifeSciences Limited (NSEI:ASTEC) for INR 0.03 million.Clean Max Enviro Energy Solutions Limited (NSEI:CLEANMAX) entered into an agreement to acquire an additional 26% stake in Clean Max Andes Private Limited from Astec LifeSciences Limited (NSEI:ASTEC) for INR 0.03 million on March 9, 2026. A cash consideration of INR 0.03 million will be paid by Clean Max Enviro Energy Solutions Limited. As part of consideration, INR 0.03 million is paid towards common equity of Clean Max Andes Private Limited. The expected completion of the transaction is March 10, 2026.
Price Target Changed • Feb 15Price target decreased by 10% to ₹758Down from ₹845, the current price target is an average from 2 analysts. New target price is 19% above last closing price of ₹637. Stock is down 25% over the past year. The company is forecast to post a net loss per share of ₹22.50 next year compared to a net loss per share of ₹68.71 last year.
Reported Earnings • Feb 01Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: ₹7.04 loss per share (improved from ₹20.60 loss in 3Q 2025). Revenue: ₹1.26b (up 34% from 3Q 2025). Net loss: ₹157.0m (loss narrowed 61% from 3Q 2025). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 44%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 20Astec LifeSciences Limited to Report Q3, 2026 Results on Jan 30, 2026Astec LifeSciences Limited announced that they will report Q3, 2026 results on Jan 30, 2026
分析記事 • Nov 25Astec LifeSciences Limited (NSE:ASTEC) Looks Just Right With A 33% Price JumpAstec LifeSciences Limited ( NSE:ASTEC ) shareholders would be excited to see that the share price has had a great...
分析記事 • Nov 21Astec LifeSciences (NSE:ASTEC) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).
Reported Earnings • Oct 31Second quarter 2026 earnings: EPS and revenues miss analyst expectationsSecond quarter 2026 results: ₹11.35 loss per share (improved from ₹19.66 loss in 2Q 2025). Revenue: ₹748.4m (down 24% from 2Q 2025). Net loss: ₹244.3m (loss narrowed 37% from 2Q 2025). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 14Astec LifeSciences Limited to Report Q2, 2026 Results on Oct 29, 2025Astec LifeSciences Limited announced that they will report Q2, 2026 results on Oct 29, 2025
New Risk • Aug 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).
Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 3 highly experienced directors. Independent Director Ganapati Yadav was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 30Astec LifeSciences Limited has completed a Follow-on Equity Offering in the amount of INR 2.376256 billion.Astec LifeSciences Limited has completed a Follow-on Equity Offering in the amount of INR 2.376256 billion. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,669,951 Price\Range: INR 890 Transaction Features: Regulation S; Rights Offering
お知らせ • Jul 11Astec LifeSciences Limited to Report Q1, 2026 Results on Jul 28, 2025Astec LifeSciences Limited announced that they will report Q1, 2026 results on Jul 28, 2025
Reported Earnings • Jul 09Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₹68.71 loss per share (further deteriorated from ₹23.94 loss in FY 2024). Revenue: ₹3.81b (down 17% from FY 2024). Net loss: ₹1.35b (loss widened 187% from FY 2024). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 25Astec LifeSciences Limited has filed a Follow-on Equity Offering in the amount of INR 2.5 billion.Astec LifeSciences Limited has filed a Follow-on Equity Offering in the amount of INR 2.5 billion. Security Name: Equity Shares Security Type: Common Stock Transaction Features: Regulation S; Rights Offering
お知らせ • Apr 24Astec LifeSciences Limited, Annual General Meeting, Jul 28, 2025Astec LifeSciences Limited, Annual General Meeting, Jul 28, 2025, at 16:00 Indian Standard Time.
Reported Earnings • Apr 24Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: ₹68.71 loss per share (further deteriorated from ₹23.94 loss in FY 2024). Revenue: ₹3.87b (down 16% from FY 2024). Net loss: ₹1.35b (loss widened 187% from FY 2024). Revenue missed analyst estimates by 39%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 16Astec LifeSciences Limited to Report Q4, 2025 Results on Apr 23, 2025Astec LifeSciences Limited announced that they will report Q4, 2025 results at 4:00 PM, Indian Standard Time on Apr 23, 2025
分析記事 • Feb 19The Price Is Right For Astec LifeSciences Limited (NSE:ASTEC) Even After Diving 30%Astec LifeSciences Limited ( NSE:ASTEC ) shareholders that were waiting for something to happen have been dealt a blow...
Price Target Changed • Feb 18Price target decreased by 8.6% to ₹1,010Down from ₹1,105, the current price target is an average from 2 analysts. New target price is 42% above last closing price of ₹710. Stock is down 24% over the past year. The company is forecast to post a net loss per share of ₹56.90 next year compared to a net loss per share of ₹23.93 last year.
New Risk • Jan 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (2.4% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change).
Reported Earnings • Jan 28Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: ₹20.59 loss per share (further deteriorated from ₹12.41 loss in 3Q 2024). Revenue: ₹957.7m (up 89% from 3Q 2024). Net loss: ₹403.8m (loss widened 66% from 3Q 2024). Revenue missed analyst estimates by 3.2%. Earnings per share (EPS) also missed analyst estimates by 102%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 98 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 20Astec LifeSciences Limited to Report Q3, 2025 Results on Jan 27, 2025Astec LifeSciences Limited announced that they will report Q3, 2025 results on Jan 27, 2025
分析記事 • Jan 04Why We're Not Concerned About Astec LifeSciences Limited's (NSE:ASTEC) Share PriceWhen you see that almost half of the companies in the Chemicals industry in India have price-to-sales ratios (or "P/S...
お知らせ • Dec 15Astec Lifesciences Limited Announces Appointment of Arijit Mukherjee as the ManagerAstec LifeSciences Limited passed resolution on December 14, 2024, Appointment of Mr. Arijit Mukherjee, Chief Operating Officer, as the "Manager" of the Company (within the meaning of Section 2(53) of the Companies Act, 2013) with effect from 26th October, 2024 for a term of 3 (Three) years, i.e., upto 25th October, 2027, has been approved by the Shareholders by way of a Special Resolution.
Reported Earnings • Oct 26Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: ₹19.66 loss per share (further deteriorated from ₹6.85 loss in 2Q 2024). Revenue: ₹1.01b (down 9.2% from 2Q 2024). Net loss: ₹385.6m (loss widened 187% from 2Q 2024). Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 04Astec Lifesciences Limited Announces Resignation of Brahma Nand Vyas as an Independent DirectorAstec LifeSciences Limited announced that Dr. Brahma Nand Vyas has tendered his resignation as an Independent Director of the Company with effect from closure of business hours on 4th October, 2024, due to his advancing age. Reason for Change: Dr. Brahma Nand Vyas has tendered his resignation as an Independent Director of the Company, with effect from closure of business hours on 4th October, 2024, due to his advancing age.
お知らせ • Sep 23Astec Lifesciences Limited Announces Resignation of Anurag Roy as Chief Executive Officer, Effective October 25, 2024Astec LifeSciences Limited announced that Mr. Anurag Roy has tendered his resignation as Chief Executive Officer with effect from closure of business hours on 25th October, 2024. Reason for Change: Mr. Anurag Roy has tendered his resignation as the Whole Time Director & Chief Executive Officer of the Company, with effect from closure of business hours on 25th October, 2024, for pursuing opportunities outside the Company. Date of Cessation: Closure of business hours on 25th October, 2024.
Price Target Changed • Sep 23Price target decreased by 14% to ₹1,090Down from ₹1,273, the current price target is an average from 2 analysts. New target price is 9.3% below last closing price of ₹1,202. Stock is down 8.4% over the past year. The company is forecast to post earnings per share of ₹10.30 next year compared to a net loss per share of ₹23.93 last year.
お知らせ • Sep 23Astec Lifesciences Limited Announces Resignation of Anurag Roy as the Whole Time Director, Effective October 25, 2024Astec LifeSciences Limited announced that Mr. Anurag Roy has tendered his resignation as the Whole Time Director of the Company with effect from closure of business hours on 25th October, 2024. Reason for Change: Mr. Anurag Roy has tendered his resignation as the Whole Time Director & Chief Executive Officer of the Company, with effect from closure of business hours on 25th October, 2024, for pursuing opportunities outside the Company. Date of Cessation: Closure of business hours on 25th October, 2024.
New Risk • Aug 07New major risk - Revenue and earnings growthEarnings have declined by 31% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (2.1% operating cash flow to total debt). Earnings have declined by 31% per year over the past 5 years.
Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. Additional Non-Executive Non- Independent Director Burjis Godrej was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Jul 23Shareholders May Be Wary Of Increasing Astec LifeSciences Limited's (NSE:ASTEC) CEO Compensation PackageKey Insights Astec LifeSciences' Annual General Meeting to take place on 29th of July Total pay for CEO Anurag Roy...
お知らせ • Jul 18Astec LifeSciences Limited to Report Q1, 2025 Results on Jul 29, 2024Astec LifeSciences Limited announced that they will report Q1, 2025 results on Jul 29, 2024
Reported Earnings • Jul 08Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: ₹23.94 loss per share (down from ₹13.04 profit in FY 2023). Revenue: ₹4.59b (down 27% from FY 2023). Net loss: ₹469.3m (down 284% from profit in FY 2023). Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 31% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
分析記事 • Jul 03Market Participants Recognise Astec LifeSciences Limited's (NSE:ASTEC) Revenues Pushing Shares 28% HigherAstec LifeSciences Limited ( NSE:ASTEC ) shareholders have had their patience rewarded with a 28% share price jump in...
お知らせ • May 03Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024Astec LifeSciences Limited, Annual General Meeting, Jul 29, 2024, at 16:00 Indian Standard Time.
Reported Earnings • May 03Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2024 results: ₹0.50 loss per share (down from ₹13.04 profit in FY 2023). Revenue: ₹1.56b (down 75% from FY 2023). Net loss: ₹9.74m (down 104% from profit in FY 2023). Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 63% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
お知らせ • May 03+ 1 more updateAstec Lifesciences Limited Announces Resignation of Mr. K. Suryanarayan as Chief Financial Officer, Effective May 3, 2024Astec LifeSciences Limited noted the resignation of Mr. K. Suryanarayan from the position of "Chief Financial Officer" of the Company with effect from the close of business hours on 3rd May, 2024.
お知らせ • Apr 26Astec LifeSciences Limited to Report Q4, 2024 Results on May 02, 2024Astec LifeSciences Limited announced that they will report Q4, 2024 results on May 02, 2024
Price Target Changed • Apr 14Price target decreased by 14% to ₹1,108Down from ₹1,285, the current price target is an average from 2 analysts. New target price is 14% below last closing price of ₹1,289. Stock is down 5.2% over the past year. The company is forecast to post a net loss per share of ₹21.70 compared to earnings per share of ₹13.04 last year.
分析記事 • Mar 15Astec LifeSciences Limited (NSE:ASTEC) Stocks Shoot Up 30% But Its P/S Still Looks ReasonableThose holding Astec LifeSciences Limited ( NSE:ASTEC ) shares would be relieved that the share price has rebounded 30...
Price Target Changed • Jan 28Price target decreased by 9.3% to ₹1,205Down from ₹1,328, the current price target is an average from 2 analysts. New target price is 20% above last closing price of ₹1,001. Stock is down 35% over the past year. The company posted earnings per share of ₹13.04 last year.
Reported Earnings • Jan 27Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023)Third quarter 2024 results: ₹12.41 loss per share (down from ₹0.43 profit in 3Q 2023). Revenue: ₹517.0m (down 56% from 3Q 2023). Net loss: ₹243.3m (down ₹251.7m from profit in 3Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 13Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024Astec LifeSciences Limited announced that they will report Q3, 2024 results at 4:00 PM, Indian Standard Time on Jan 25, 2024
Reported Earnings • Oct 29Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023)Second quarter 2024 results: ₹6.85 loss per share (down from ₹9.34 profit in 2Q 2023). Revenue: ₹1.12b (down 44% from 2Q 2023). Net loss: ₹134.3m (down 173% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
お知らせ • Oct 11Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023Astec LifeSciences Limited announced that they will report Q2, 2024 results on Oct 27, 2023
お知らせ • Jul 29Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023Astec LifeSciences Limited announced at the AGM held on July 27, 2023, approved to declare final dividend on equity share @15%(that is INR 1.5) per equity share of face value of INR 10 for the financial year ended March 31, 2023.
お知らせ • Jul 23Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023Astec LifeSciences Limited announced that they will report Q1, 2024 results on Jul 27, 2023
Upcoming Dividend • Jul 14Upcoming dividend of ₹1.50 per share at 0.1% yieldEligible shareholders must have bought the stock before 21 July 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 12% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.9%).
Reported Earnings • Jul 08Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)Full year 2023 results: EPS: ₹13.04 (down from ₹45.87 in FY 2022). Revenue: ₹6.28b (down 7.2% from FY 2022). Net income: ₹255.6m (down 72% from FY 2022). Profit margin: 4.1% (down from 13% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Jun 10Non-Executive Non-Independent Director recently sold ₹4.8m worth of stockOn the 6th of June, Balram Yadav sold around 3k shares on-market at roughly ₹1,407 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
分析記事 • May 17Astec LifeSciences (NSE:ASTEC) Could Be Struggling To Allocate CapitalThere are a few key trends to look for if we want to identify the next multi-bagger. In a perfect world, we'd like to...
お知らせ • May 04Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023Astec LifeSciences Limited at its board meeting held on May 2, 2023, recommended Final Dividend of 15% on the Equity Share Capital of the Company that is INR 1.50 per Equity Share of Face Value of INR 10 each for the Financial Year ended March 31, 2023, subject To Approve the Shareholders at the upcoming 29th Annual General Meeting of the Company. The Book Closure Dates for the purposes of the 29th Annual General Meeting and payment of Final Dividend are from July 22, 2023 to July 26, 2023, during which the Register of Members and Share Transfer Books will remain closed. The dividend will be paid by August 1, 2023.
Reported Earnings • May 03Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)Full year 2023 results: EPS: ₹13.04 (down from ₹45.87 in FY 2022). Revenue: ₹6.41b (down 5.3% from FY 2022). Net income: ₹255.6m (down 72% from FY 2022). Profit margin: 4.0% (down from 13% in FY 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹1,346, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 204% over the past three years.
Reported Earnings • Jan 31Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022)Third quarter 2023 results: EPS: ₹0.43 (down from ₹12.63 in 3Q 2022). Revenue: ₹1.21b (down 30% from 3Q 2022). Net income: ₹8.40m (down 97% from 3Q 2022). Profit margin: 0.7% (down from 14% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jan 12Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023Astec LifeSciences Limited announced that they will report Q3, 2023 results on Jan 30, 2023
Price Target Changed • Jan 05Price target decreased to ₹1,923Down from ₹2,083, the current price target is an average from 3 analysts. New target price is 11% above last closing price of ₹1,739. Stock is up 19% over the past year. The company is forecast to post earnings per share of ₹46.90 for next year compared to ₹45.87 last year.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive Non- Independent Director Burjis Godrej was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 03Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022)Second quarter 2023 results: EPS: ₹9.34 (up from ₹4.63 in 2Q 2022). Revenue: ₹2.00b (up 95% from 2Q 2022). Net income: ₹183.1m (up 102% from 2Q 2022). Profit margin: 9.2% (up from 8.8% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 17Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹2,176, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 525% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹3,619 per share.
分析記事 • Oct 14Shareholders Are Optimistic That Astec LifeSciences (NSE:ASTEC) Will Multiply In ValueIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Price Target Changed • Aug 30Price target increased to ₹2,132Up from ₹1,875, the current price target is an average from 2 analysts. New target price is 10% above last closing price of ₹1,930. Stock is up 48% over the past year. The company is forecast to post earnings per share of ₹50.00 for next year compared to ₹45.87 last year.
Board Change • Aug 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Additional Non-Executive Non- Independent Director Burjis Godrej was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Jul 27We Ran A Stock Scan For Earnings Growth And Astec LifeSciences (NSE:ASTEC) Passed With EaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Upcoming Dividend • Jul 12Upcoming dividend of ₹1.50 per shareEligible shareholders must have bought the stock before 19 July 2022. Payment date: 29 July 2022. Payout ratio is a comfortable 3.3% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.8%). Lower than average of industry peers (0.8%).
Reported Earnings • Jul 06Full year 2022 earnings: Revenues exceed analyst expectationsFull year 2022 results: Net income: ₹898.6m (up 38% from FY 2021). Revenue exceeded analyst estimates by 3.8%.
分析記事 • Jun 28Here's Why Astec LifeSciences (NSE:ASTEC) Can Manage Its Debt ResponsiblyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jun 03A Look At The Intrinsic Value Of Astec LifeSciences Limited (NSE:ASTEC)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Astec LifeSciences...
Price Target Changed • May 19Price target increased to ₹1,869Up from ₹1,722, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹1,794. Stock is up 43% over the past year. The company is forecast to post earnings per share of ₹54.93 for next year compared to ₹45.87 last year.
Major Estimate Revision • May 09Consensus revenue estimates increase by 11%The consensus outlook for revenues in 2023 has improved. 2023 revenue forecast increased from ₹7.68b to ₹8.52b. EPS estimate increased from ₹48.30 to ₹54.93 per share. Net income forecast to grow 24% next year vs 25% growth forecast for Chemicals industry in India. Consensus price target up from ₹1,722 to ₹1,812. Share price fell 3.9% to ₹1,874 over the past week.
分析記事 • May 08Analysts Just Published A Bright New Outlook For Astec LifeSciences Limited's (NSE:ASTEC)Shareholders in Astec LifeSciences Limited ( NSE:ASTEC ) may be thrilled to learn that the analysts have just delivered...
分析記事 • May 06Astec LifeSciences Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsAstec LifeSciences Limited ( NSE:ASTEC ) investors will be delighted, with the company turning in some strong numbers...
Reported Earnings • May 04Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: ₹45.87 (up from ₹33.23 in FY 2021). Revenue: ₹6.87b (up 23% from FY 2021). Net income: ₹898.6m (up 38% from FY 2021). Profit margin: 13% (up from 12% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.8%. Earnings per share (EPS) also surpassed analyst estimates by 6.9%. Over the next year, revenue is forecast to grow 12%, compared to a 21% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
Recent Insider Transactions • Apr 02MD & Director recently bought ₹37m worth of stockOn the 25th of March, Ashok Hiremath bought around 22k shares on-market at roughly ₹1,701 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹213m more in shares than they bought in the last 12 months.
Recent Insider Transactions • Mar 11Non-Executive Non-Independent Director recently bought ₹1.5m worth of stockOn the 7th of March, Balram Yadav bought around 1k shares on-market at roughly ₹1,481 per share. In the last 3 months, they made an even bigger purchase worth ₹3.5m. Despite this recent purchase, insiders have collectively sold ₹251m more in shares than they bought in the last 12 months.
Recent Insider Transactions • Mar 06Non-Executive Non-Independent Director recently bought ₹3.5m worth of stockOn the 28th of February, Balram Yadav bought around 2k shares on-market at roughly ₹1,467 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹252m more in shares than they bought in the last 12 months.
Reported Earnings • Jan 26Third quarter 2022 earnings: EPS and revenues exceed analyst expectationsThird quarter 2022 results: EPS: ₹12.63 (up from ₹3.61 in 3Q 2021). Revenue: ₹1.75b (up 51% from 3Q 2021). Net income: ₹247.5m (up 251% from 3Q 2021). Profit margin: 14% (up from 6.1% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 19%. Over the next year, revenue is forecast to grow 24%, compared to a 19% growth forecast for the industry in India. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Jan 25Why We Like The Returns At Astec LifeSciences (NSE:ASTEC)To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...
Recent Insider Transactions • Dec 18Insider recently sold ₹1.5m worth of stockOn the 13th of December, Ramesh Pingale sold around 1k shares on-market at roughly ₹1,508 per share. In the last 3 months, they made an even bigger sale worth ₹2.4m. Insiders have been net sellers, collectively disposing of ₹254m more than they bought in the last 12 months.
Recent Insider Transactions • Dec 18Insider recently sold ₹1.5m worth of stockOn the 13th of December, Ramesh Pingale sold around 1k shares on-market at roughly ₹1,508 per share. In the last 3 months, they made an even bigger sale worth ₹2.4m. Insiders have been net sellers, collectively disposing of ₹254m more than they bought in the last 12 months.
分析記事 • Dec 13Is Astec LifeSciences (NSE:ASTEC) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹1,553, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 202% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹952 per share.
Recent Insider Transactions • Nov 20Insider recently sold ₹2.4m worth of stockOn the 15th of November, Ramesh Pingale sold around 2k shares on-market at roughly ₹1,401 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹253m more than they bought in the last 12 months.
Price Target Changed • Nov 16Price target increased to ₹1,508Up from ₹1,392, the current price target is an average from 3 analysts. New target price is 10% above last closing price of ₹1,367. Stock is up 39% over the past year. The company is forecast to post earnings per share of ₹39.25 for next year compared to ₹33.23 last year.
Price Target Changed • Aug 01Price target increased to ₹1,386Up from ₹1,284, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of ₹1,388. Stock is up 48% over the past year.
分析記事 • Jul 21We Take A Look At Why Astec LifeSciences Limited's (NSE:ASTEC) CEO Has Earned Their Pay PacketWe have been pretty impressed with the performance at Astec LifeSciences Limited ( NSE:ASTEC ) recently and CEO Ashok...
